A Preliminary in Silico Lead Series of 2-phthalimidinoglutaric Acid Analogues Designed As Mmp-3 Inhibitors.
From: Department of Chemistry and Minnesota Supercomputing Institute, University of Minnesota, 207 Pleasant St SE, Minneapolis, Minnesota 55455, USA. amni@chem.umn.edu
Journal of chemical information and modeling
- Publish Date:
- ISSN: 1549-9596
- Volume: 46
- Issue: 5
- Pages: 2104-9
- Medium: Print
- Language: English
- Citation (JAMA): Amin Elizabeth A, Welsh William J, et al. A Preliminary in Silico Lead Series of 2-phthalimidinoglutaric Acid Analogues Designed As Mmp-3 Inhibitors.. ;46:2104-9
Abstract
Matrix metalloproteinases (MMPs) have been the subject of intense research because of their roles in tumor metastasis and in the rise and spread of degenerative diseases such as osteo- and rheumatoid arthritis. A preliminary class of 140 druglike, small-molecule matrix metalloproteinase-3 inhibitors, intended as starting scaffolds for optimization and synthesis, has been designed in silico using a series of highly predictive three-dimensional quantitative structure-activity relationship models, including comparative molecular field analysis and comparative molecular similarity indices analysis, with docking and scoring. Thalidomide was chosen as the skeleton on which to base the new lead series, as it moderately inhibits MMP-3, is antiangiogenic, and lends itself easily to structural modifications. Most of the new compounds demonstrate medium to high predicted biological activity and good bioavailability as estimated by the octanol-water partition coefficient ClogP. Compound 102 in particular exhibits extremely favorable predicted activity against MMP-3; is moderately bioavailable; satisfies Lipinski’s Rule of Five; and shows promise for further optimization, synthesis, and experimental evaluation as a potential adjunct anticancer or antirheumatic therapeutic.
Mesh Headings (Keywords): Binding Sites, Glutarates, Matrix Metalloproteinase 3, Models, Molecular, Protease Inhibitors, Quantitative Structure-Activity Relationship, Thalidomide
Check for Full Text / PubMed Unique Identifier (PMID): 16995741
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.